

# D ThaÃ§i

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1683500/publications.pdf>

Version: 2024-02-01

221  
papers

14,609  
citations

24978

57  
h-index

22102

113  
g-index

254  
all docs

254  
docs citations

254  
times ranked

9608  
citing authors

#	ARTICLE	IF	CITATIONS
1	High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study. <i>Modern Rheumatology</i> , 2022, 32, 87-95.	0.9	2
2	Long-term topical management of psoriasis: the road ahead. <i>Journal of Dermatological Treatment</i> , 2022, 33, 111-120.	1.1	37
3	Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12. <i>Journal of Dermatological Treatment</i> , 2022, 33, 54-61.	1.1	7
4	Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1749-1753.	1.1	6
5	Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1608-1616.	1.1	14
6	Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2022, 186, 30-39.	1.4	9
7	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	1.1	17
8	Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-1. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 60-67.	1.3	6
9	Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary. <i>Immunotherapy</i> , 2022, 14, 5-14.	1.0	7
10	Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 51-64.	3.3	56
11	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	1.4	30
12	Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes. <i>Rheumatology and Therapy</i> , 2022, 9, 621-635.	1.1	9
13	A Digital Health Application Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Proof-of-Concept Data from a Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1117.	1.0	7
14	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00683.	0.6	9
15	Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. <i>SKIN the Journal of Cutaneous Medicine</i> , 2022, 6, s4.	0.1	3
16	Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 735.	2.0	22
17	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , 2021, 184, 652-662.	1.4	15
18	Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 981-987.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1269-1277.	0.6	38
20	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate to severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2021, 184, 548-550.	1.4	4
21	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 476-485.	1.3	101
22	Dupilumab provides favourable long-term safety and efficacy in children aged 6 to 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. <i>British Journal of Dermatology</i> , 2021, 184, 857-870.	1.4	45
23	Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 35-41.	1.3	12
24	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1101-1112.	13.9	239
25	Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1212-1223.e6.	2.0	31
26	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. <i>British Journal of Dermatology</i> , 2021, 185, 1160-1168.	1.4	21
27	A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. <i>Joint Bone Spine</i> , 2021, 88, 105175.	0.8	14
28	Prevalence and presumptive triggers of localized bullous pemphigoid. <i>Journal of Dermatology</i> , 2021, 48, 1257-1261.	0.6	10
29	POS1042...EFFICACY AND SAFETY OF DELUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYPK PSO-1 STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 795.1-796.	0.5	21
30	Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. <i>British Journal of Dermatology</i> , 2021, 185, 323-334.	1.4	55
31	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet, The</i> , 2021, 397, 2151-2168.	6.3	259
32	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate to severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e709-e711.	1.3	2
33	Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1686-1691.	1.3	12
34	Laboratory Safety of Dupilumab in Patients Aged 6 to 11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. <i>Paediatric Drugs</i> , 2021, 23, 515-527.	1.3	15
35	27464 Bimekizumab vs adalimumab in plaque psoriasis: Higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, AB146.	0.6	0
36	27596 Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, AB154.	0.6	0

#	ARTICLE	IF	CITATIONS
37	26573 Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, AB107.	0.6	0
38	Documentation of psoriasis in routine care – expert consensus on a German data set. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1463-1475.	0.4	8
39	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021, 11, 2147-2157.	1.4	4
40	Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. <i>SKIN the Journal of Cutaneous Medicine</i> , 2021, 5, s37.	0.1	4
41	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. <i>Dermatology and Therapy</i> , 2021, 11, 1643-1656.	1.4	1
42	Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase). <i>Journal of Drugs in Dermatology</i> , 2021, 20, 436-441.	0.4	5
43	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020, 182, 605-617.	1.4	103
44	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	0.6	155
45	Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase II a open-label trial and subsequent phase III open-label extension. <i>British Journal of Dermatology</i> , 2020, 182, 85-96.	1.4	111
46	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. <i>British Journal of Dermatology</i> , 2020, 182, 869-879.	1.4	31
47	Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). <i>British Journal of Dermatology</i> , 2020, 183, 265-275.	1.4	24
48	Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 310-318.	1.3	25
49	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 131.	2.0	110
50	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 877-884.	1.5	242
51	14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2). <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB16.	0.6	2
52	13601 BMS-986165, an oral selective TYK2 inhibitor, in the treatment of moderate to severe psoriasis as assessed by the static Physicians Global Assessment/body surface area composite tool, a clinically useful alternative to the Psoriasis Area and Severity Index score. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB120.	0.6	0
53	15001 Durable efficacy of certolizumab pegol dosed at 400 mg every two weeks over 128 weeks in patients with plaque psoriasis enrolled in three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT). <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB139.	0.6	0
54	15910 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB163.	0.6	0

#	ARTICLE	IF	CITATIONS
55	16830 Results from the open-label treatment period of a long-term proactive management phase III trial using fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB187.	0.6	0
56	18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB208.	0.6	0
57	12797 Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB1.	0.6	0
58	14998 Reductions in absolute PASI over 144 weeks of treatment with certolizumab pegol in patients with plaque psoriasis: Pooled analysis from two phase 3 trials (CIMPASI-1 and CIMPASI-2). <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB138.	0.6	0
59	15026 BMS-986165, an oral selective tyrosine kinase 2 inhibitor: Evaluation of changes in laboratory parameters in response to treatment in a phase 2 trial in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB140.	0.6	2
60	15807 Efficacy of tildrakizumab in patients with moderate to severe psoriasis according to disease duration: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB160.	0.6	1
61	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 267-278.	0.3	10
62	Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey. <i>Rheumatology and Therapy</i> , 2020, 7, 617-637.	1.1	17
63	<p>Spotlight on Topical Long-Term Management of Plaque Psoriasis</p>. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020, Volume 13, 495-498.	0.8	8
64	Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1478-1480.	0.4	9
65	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020, 10, e039928.	0.8	8
66	Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series. <i>Frontiers in Medicine</i> , 2020, 7, 543944.	1.2	13
67	Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). <i>Dermatology and Therapy</i> , 2020, 10, 663-670.	1.4	28
68	Dupilumab for treatment of refractory prurigo nodularis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 618-624.	0.4	12
69	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 567-577.	3.3	78
70	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1282-1293.	0.6	214
71	A study of the drug tildrakizumab in psoriasis patients. <i>British Journal of Dermatology</i> , 2020, 182, e100.	1.4	0
72	ä,€é;1âœ"é"¶â±ç—...æ,£è€...ã,â¼/4€â±•çš,, tildrakizumab èç%©ç"ç©¶. <i>British Journal of Dermatology</i> , 2020, 182, 1113.		0

#	ARTICLE	IF	CITATIONS
73	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. <i>PLoS ONE</i> , 2020, 15, e0235091.	1.1	17
74	Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2809-2820.	1.3	13
75	Secukinumab-induced chronic discoid lupus erythematosus. <i>JAAD Case Reports</i> , 2020, 6, 362-364.	0.4	10
76	A trial to compare the biologic drug ixekizumab with two other treatments for psoriasis, fumaric acid esters and methotrexate. <i>British Journal of Dermatology</i> , 2020, 182, e138.	1.4	0
77	Alopecia areata development in atopic dermatitis patients treated with dupilumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e612-e613.	1.3	17
78	BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s28.	0.1	6
79	Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s32.	0.1	1
80	AB0759...FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1677.1-1677.	0.5	1
81	AB1289-HPR...PERCEPTION OF THE VALUE OF DRUGS ON DIFFERENT MANIFESTATIONS OF PSORIATIC ARTHRITIS BASED ON A MULTI-STAGE EXPERT OPINION SURVEY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1934.2-1935.	0.5	0
82	General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101108.	0.9	11
83	An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s73.	0.1	1
84	Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1405-1409.	0.6	14
85	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet</i> , 2019, 394, 576-586.	6.3	198
86	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1215-1219.	0.5	29
87	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 443-456.	3.3	130
88	Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. <i>British Journal of Dermatology</i> , 2019, 181, 1177-1189.	1.4	28
89	Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). <i>Journal of Dermatological Science</i> , 2019, 94, 266-275.	1.0	121
90	Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 1254-1264.	1.4	57



#	ARTICLE	IF	CITATIONS
91	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1098-1106.	1.3	19
92	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , 2019, 182, 67-75.	1.4	7
93	Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1116-1123.	1.3	20
94	Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. <i>British Journal of Dermatology</i> , 2019, 181, 80-87.	1.4	49
95	Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1054-1062.	0.3	150
96	FRIO452...TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES. , 2019, , .		0
97	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 76-85.	1.4	23
98	IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. <i>Journal of Autoimmunity</i> , 2019, 96, 104-112.	3.0	85
99	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019, 180, 67-75.	1.4	33
100	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019, 181, 358-365.	1.4	42
101	Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 700-708.	1.3	78
102	Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 709-717.	1.3	17
103	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. <i>Frontiers in Immunology</i> , 2019, 10, 3096.	2.2	122
104	Best-practice Indicators in Psoriatic Disease Care. <i>Journal of Rheumatology</i> , 2019, 95, 38-45.	1.0	5
105	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and ) <a href="#">TJ ETQq1 1 0.784314.rgBT /Overlook 101</a>		
106	Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (<sc>SCULPTURE</sc> Extension Study). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1507-1514.	1.3	160
107	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 741-748.	0.6	22
108	The role of the microbiome in psoriasis: moving from disease description to treatment selection?. <i>British Journal of Dermatology</i> , 2018, 178, 1020-1027.	1.4	54

#	ARTICLE	IF	CITATIONS
109	Multiple switches between <sc>GP</sc> 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque psoriasis: 30-week results from the phase 3, confirmatory <sc>EGALITY</sc> study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 420-427.	1.3	70
110	Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the <sc>PROSPECT</sc> study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 411-419.	1.3	15
111	Cost of illness of psoriasis – results of a German cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 174-180.	1.3	30
112	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. British Journal of Dermatology, 2018, 178, 1083-1101.	1.4	380
113	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. Journal of the American Association of Nurse Practitioners, 2018, 30, 529-541.	0.5	11
114	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. British Journal of Dermatology, 2018, 179, 1385-1391.	1.4	25
115	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. New England Journal of Medicine, 2018, 379, 1313-1321.	13.9	301
116	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology, 2018, 57, 1777-1788.	0.9	27
117	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. British Journal of Dermatology, 2018, 179, 615-622.	1.4	57
118	Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). Journal of the American Academy of Dermatology, 2017, 77, 310-317.e1.	0.6	148
119	Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1271-1284.	1.3	21
120	Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 40-49.	6.3	120
121	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) Tj ETQq1 1 0,784314 reBT / O 6,3 428	6.3	428
122	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. British Journal of Dermatology, 2017, 177, 1024-1032.	1.4	48
123	Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. British Journal of Dermatology, 2017, 177, 1033-1042.	1.4	54
124	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet, The, 2017, 389, 2317-2327.	6.3	316
125	Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatology and Therapy, 2017, 7, 365-381.	1.4	33
126	Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. Dermatology and Therapy, 2017, 7, 265-279.	1.4	31



#	ARTICLE	IF	CITATIONS
127	Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". <i>Journal of Investigative Dermatology</i> , 2017, 137, 2642-2644.	0.3	2
128	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 928-938.	1.4	155
129	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 498-506.	1.3	28
130	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 60-69.e9.	0.6	258
131	Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e191-e192.	1.3	42
132	THU0431...Sustained Improvements in Skin Symptoms, Physical Functioning, and Quality of Life with Secukinumab versus Ustekinumab in Patients with Moderate-To-Severe Psoriasis and Concomitant Psoriatic Arthritis: 52 Week Results from The Clear Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 345.2-346.	0.5	0
133	Impact on quality of life of alitretinoin in severe chronic hand eczema: FUGETTA real-world study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1261-1270.	0.4	10
134	The German National Program on Psoriasis Health Care 2005-2015: results and experiences. <i>Archives of Dermatological Research</i> , 2016, 308, 389-400.	1.1	47
135	Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1162-1170.e3.	0.6	57
136	Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis. <i>Rheumatology</i> , 2016, 55, 1791-1795.	0.9	31
137	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 273-286.	1.4	378
138	Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study. <i>Journal of Dermatological Treatment</i> , 2016, 27, 577-583.	1.1	19
139	Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study. <i>Journal of Rheumatology</i> , 2016, 43, 632-639.	1.0	31
140	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 841-850.	0.6	135
141	Patient-relevant treatment goals in psoriasis. <i>Archives of Dermatological Research</i> , 2016, 308, 69-78.	1.1	92
142	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 239-254.	0.6	577
143	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet</i> , 2016, 387, 40-52.	6.3	471
144	Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). <i>British Journal of Dermatology</i> , 2015, 173, 777-787.	1.4	67

#	ARTICLE	IF	CITATIONS
145	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , 2015, 173, 930-939.	1.4	236
146	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. <i>British Journal of Dermatology</i> , 2015, 173, 949-961.	1.4	253
147	Stellenwert der Basistherapie bei Psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 415-418.	0.4	6
148	Pictorial representation of illness and self measure (<sc>PRISM</sc>): an effective tool to assess the burden of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2356-2362.	1.3	18
149	Seborrhoeic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL-5010). <i>British Journal of Dermatology</i> , 2015, 173, 247-249.	1.4	6
150	Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. <i>Archives of Dermatological Research</i> , 2015, 307, 875-883.	1.1	124
151	Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the <sc>BELIEVE</sc> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 353-360.	1.3	75
152	Association between Skin and Joint Involvement in Patients with Psoriatic Arthritis Treated with Adalimumab: Analysis of Data from a German Non-Interventional Study. <i>Dermatology</i> , 2015, 230, 213-221.	0.9	4
153	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 410-419.e6.	0.6	55
154	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 400-409.	0.6	472
155	Importance of basic therapy in psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 415-418.	0.4	16
156	Aktuelle klinische Entwicklungen zur Behandlung chronisch entzündlicher Hautkrankheiten (Psoriasis, Ekzemkrankheiten). <i>Allergologie</i> , 2015, 38, 153-162.	0.1	1
157	GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: A Meeting Report. <i>Journal of Rheumatology</i> , 2014, 41, 1197-1199.	1.0	3
158	Topical long-term therapy of psoriasis with vitamin D <sub>3</sub> analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 667-682.	0.4	29
159	Validation of Dermaphot® for the assessment of steroid-induced skin atrophy. <i>Archives of Dermatological Research</i> , 2014, 306, 311-311.	1.1	0
160	Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate to severe psoriasis: results from the PRISTINE trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 900-906.	1.3	48
161	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <sc>TRANSIT</sc> randomized trial in moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.4	37
162	Diagnosing and treating psoriatic arthritis: an update. <i>British Journal of Dermatology</i> , 2014, 170, 772-786.	1.4	28

#	ARTICLE	IF	CITATIONS
163	Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2014, 371, 130-139.	13.9	1,148
164	Validation of Dermaphot® for the assessment of steroid-induced skin atrophy. <i>Archives of Dermatological Research</i> , 2013, 305, 215-221.	1.1	5
165	Recommendations for detection of individual risk for comorbidities in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2013, 305, 91-98.	1.1	44
166	Vascular Endothelial Growth Factor C-Induced Lymphangiogenesis Decreases Tumor Interstitial Fluid Pressure and Tumor. <i>Translational Oncology</i> , 2013, 6, 398-404.	1.7	16
167	Modeling Pattern Formation in Skin Diseases by a Cellular Automaton. <i>Journal of Investigative Dermatology</i> , 2013, 133, 567-571.	0.3	6
168	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 729-735.	0.6	397
169	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2013, 168, 402-411.	1.4	118
170	Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e376-83.	1.3	93
171	Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS). <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 429-435.	0.4	20
172	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. <i>European Journal of Dermatology</i> , 2012, 22, 762-769.	0.3	25
173	Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 448-455.	1.3	21
174	'Nosing around' the human skin: What information is concealed in skin odour?. <i>Experimental Dermatology</i> , 2012, 21, 655-659.	1.4	29
175	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2012, 168, no-no.	1.4	199
176	Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1012-1020.	1.3	47
177	Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1187-1193.	1.3	106
178	Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. <i>Experimental Dermatology</i> , 2011, 20, 130-133.	1.4	21
179	Periorale Dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 422-428.	0.4	13
180	Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. <i>Archives of Dermatological Research</i> , 2011, 303, 381-388.	1.1	66

#	ARTICLE	IF	CITATIONS
181	Subcutaneous Immunotherapy with a Depigmented Polymerized Birch Pollen Extract â€œ A New Therapeutic Option for Patients with Atopic Dermatitis. International Archives of Allergy and Immunology, 2011, 155, 252-256.	0.9	37
182	Management of Psoriasis in Africa and the Middle East: A Review of Current Opinion, Practice and Opportunities for Improvement. Journal of International Medical Research, 2011, 39, 1573-1588.	0.4	14
183	Ligation of Î²4 integrins activates PKB/Akt and ERK1/2 by distinct pathwaysâ€™ relevance of the keratin filament. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 940-950.	1.9	14
184	Twiceâ€™weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12â€™months. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1040-1046.	1.3	40
185	A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. British Journal of Dermatology, 2010, 163, 402-411.	1.4	99
186	Composite Measures in Psoriatic Arthritis: GRAPPA 2008. Journal of Rheumatology, 2010, 37, 453-461.	1.0	26
187	Percutaneous Absorption of Pimecrolimus Is Not Increased in Patients with Moderate to Severe Atopic Dermatitis when Pimecrolimus Cream 1% Is Applied under Occlusion. Dermatology, 2010, 221, 342-351.	0.9	8
188	Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clinics in Dermatology, 2010, 28, 52-56.	0.8	79
189	Oligonucleotides suppress PKB/Akt and act as superinductors of apoptosis in human keratinocytes. Nucleic Acids Research, 2009, 37, 3850-3864.	6.5	3
190	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis and Rheumatism, 2009, 61, 1235-1242.	6.7	104
191	Red ear syndrome and auricular erythromelalgia: the same condition?. Clinical and Experimental Dermatology, 2009, 34, e626-e628.	0.6	28
192	Efficacy and safety of fumaric acid esters in the longâ€™term treatment of psoriasis â€œ A retrospective study (FUTURE). JDDG - Journal of the German Society of Dermatology, 2009, 7, 603-610.	0.4	82
193	Topical Methyl Aminolevulinate Photodynamic Therapy Using Red Light-Emitting Diode Light for Multiple Actinic Keratoses. Dermatologic Surgery, 2009, 35, 586-592.	0.4	81
194	Topical calcineurin inhibitors for the treatment of vulvar dermatoses. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 146, 22-29.	0.5	42
195	Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Archives of Dermatological Research, 2008, 300, 101-105.	1.1	31
196	Long-term data in the treatment of psoriasis. British Journal of Dermatology, 2008, 159, 18-24.	1.4	28
197	Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. British Journal of Dermatology, 2008, 159, 1348-1356.	1.4	155
198	Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. Toxicology in Vitro, 2008, 22, 747-759.	1.1	53

#	ARTICLE	IF	CITATIONS
199	A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 34-40.	0.6	45
200	Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients. <i>Dermatology</i> , 2007, 215, 3-17.	0.9	30
201	Oligonucleotides Suppress IL-8 in Skin Keratinocytes In Vitro and Offer Anti-Inflammatory Properties In Vivo. <i>Journal of Investigative Dermatology</i> , 2007, 127, 846-854.	0.3	25
202	Psoriasis: a possible risk factor for development of coronary artery calcification. <i>British Journal of Dermatology</i> , 2007, 156, 271-276.	1.4	326
203	Psoriasis patients show signs of insulin resistance. <i>British Journal of Dermatology</i> , 2007, 157, 1249-1251.	1.4	227
204	Cutaneous leishmaniasis: Clinical report of two cases and review of the recent literature. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 770-772.	0.4	9
205	Use of Calcipotriene Cream (Dovonex® Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex®). <i>American Journal of Clinical Dermatology</i> , 2006, 7, 177-184.	3.3	32
206	Restoration of E-cadherin sensitizes human melanoma cells for apoptosis. <i>Melanoma Research</i> , 2006, 16, 393-403.	0.6	8
207	Treatment of scabies with 5% permethrin cream: results of a German multicenter study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, 407-413.	0.4	35
208	Leflunomide Improves Psoriasis in Patients with Psoriatic Arthritis: An In-Depth Analysis of Data from the TOPAS Study. <i>Dermatology</i> , 2006, 212, 238-249.	0.9	59
209	Improved enantioselective analysis of polyunsaturated hydroxy fatty acids in psoriatic skin scales using high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 323-328.	1.2	25
210	Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. <i>British Journal of Dermatology</i> , 2005, 152, 1048-1050.	1.4	23
211	Complicated mycosis fungoides mimicking facial erysipelas. <i>British Journal of Dermatology</i> , 2005, 152, 1381-1383.	1.4	7
212	Detection of human beta defensin-1 and ?2 by RT-competitive multiplex PCR. <i>Archives of Dermatological Research</i> , 2005, 296, 539-542.	1.1	2
213	Successful Treatment of Acrodermatitis Continua of Hallopeau with Sequential Combination of Calcipotriol and Tacrolimus Ointments. <i>Dermatology</i> , 2005, 211, 351-355.	0.9	22
214	Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1183-1188.	1.5	66
215	Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 734-739.	0.6	56
216	Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. <i>Contact Dermatitis</i> , 2003, 49, 80-84.	0.8	76

#	ARTICLE	IF	CITATIONS
217	Occlusive Treatment of Chronic Hand Dermatitis with Pimecrolimus Cream 1% Results in Low Systemic Exposure, Is Well Tolerated, Safe, and Effective. <i>Dermatology</i> , 2003, 207, 37-42.	0.9	58
218	Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis. <i>Dermatology</i> , 2002, 205, 383-388.	0.9	46
219	Calcipotriol Solution for the Treatment of Scalp Psoriasis: Evaluation of Efficacy, Safety and Acceptance in 3,396 Patients. <i>Dermatology</i> , 2001, 203, 153-156.	0.9	65
220	Heavy Naphthen Oil Exhibits Antipsoriatic Efficacy In Vivo and Antiproliferative as Well as Differentiation-Inducing Effects on Keratinocytes In Vitro. <i>Archives of Dermatology</i> , 2000, 136, 678-679.	1.7	2
221	Tacalcitol in combination with UVB " in vitro effects. <i>Journal of Dermatological Treatment</i> , 1998, 9, S31-S35.	1.1	1